Take a look; CYBX, TA, OREX

Cyberonics Inc. ( NASDAQ: CYBX ), late on Tuesday, announced that the U.S. FDA
approved its AspireHC generator for use in vagus nerve simulation therapy. The
company said that AspireHC is expected to be in limited commercial release in
the U.S. in its third quarter, which ends on April 29, 211. Cyberonics shares
have a 52-week range of $16.55-$35.32. The stock is currently trading above its
50-day ad 200-day moving averages. In the last one year, the stock gained
78.38%. Cyberonics is a Houston, Texas-based medical technology company, with
core expertise in neuromodulation. The company is engaged in the development and
marketing of VNS Therapy System. TravelCenters of America LLC ( AMEX: TA )
shares saw a huge rally on Tuesday after Hospitality Properties Trust (NYSE:
HPT) amended its lease agreements. The company announced on Tuesday that it
entered amendments to its lease agreements with Hospitality Properties, which
will reduce the company's current rent. TravelCenters of America shares have a
52-week range of $2.05-$9.25. The stock is currently trading above its 50-day
and 200-day moving averages. The stock climbed more than 100% on Tuesday.
TravelCenters operates travel centers mainly along the U.S. interstate highway
system. The company is based in Westlake, Ohio. Orexigen Therapeutics Inc. (
NASDAQ: OREX ) shares plunged more than 70% on Tuesday after the company's new
drug application for Contrave received a negative response from the U.S. FDA.
The FDA, late on Monday, asked the company to conduct further trials to evaluate
the safety of Contrave. Orexigen shares, which had been rallying ahead of the
FDA's decision, fell more than 70% on Tuesday. The stock is now trading below
its 50-day and 200-day moving averages. Orexigen is a San Diego,
California-based biopharmaceutical company, focusing on the development and
commercialization of product candidates for the treatment of obesity. This
corporate profile is provided for information purposes only and should not be
used as the basis for any investment decision. We are neither licensed nor
qualified to provide investment advice. We were not paid, nor do we hold a
position in these stocks. We reserve the right to buy or sell any stock
mentioned in this report at any time after this post.